SSY Pharmaceutical Research Institute SSY Pharmaceutical Research Institute

Corporate email

中文/EN

简体中文

English

NEWS CENTER

Group Announcement

Media reports

Group News

Shijiazhuang Fourth Pharmaceutical Group’s Urapidil active pharmaceutical ingredient has been approved.

Category:

Group Announcement

Time：2023-05-13

Shijiazhuang Fourth Pharmaceutical Group has been receiving frequent good news in new product development. On May 12, the group’s application for urapidil was approved by the National Medical Products Administration, officially registering it as an active pharmaceutical ingredient (API) for use in marketed formulations. This marks the group’s eighth newly approved API this year.
Shijiazhuang Fourth Pharmaceutical Group’s Urapidil active pharmaceutical ingredient has been approved.
Shijiazhuang Fourth Pharmaceutical Group’s Urapidil active pharmaceutical ingredient has been approved.
Shijiazhuang Sihua Pharmaceutical Group has been receiving frequent good news regarding the development of new products. On May 12, the group’s application for uradil was approved by the National Medical Products Administration, officially registering it as an active pharmaceutical ingredient (API) for use in marketed formulations. This marks the group’s eighth newly approved API product this year.
It is understood that urapidil is a highly selective alpha-receptor blocker, primarily used for the treatment of hypertension, especially severe hypertension.
Previously, on May 8, the group’s newly submitted applications for two active pharmaceutical ingredients—urapidil hydrochloride and tofacitinib citrate—were approved on the same day. As of now, the group has obtained a total of 26 approvals for various new products this year, maintaining a consistently leading level of R&D efficiency within the industry.
In recent years, the Siyao Group has actively implemented a “API + Formulation” development strategy. The research and development, production, and export of active pharmaceutical ingredients have maintained strong growth momentum, increasingly serving as a crucial support for the company’s innovative, green, and high-quality development.

Keywords:

Previous

Shijiazhuang Sihua Pharmaceutical Group’s new product, Cinacalcet Hydrochloride Tablets, has been approved.

Shijiazhuang Fourth Pharmaceutical Group’s Sodium Acetate Ringer’s Injection Has Passed the Consistency Evaluation for Generic Drug Quality and Efficacy.

Next

Previous:

Shijiazhuang Sihua Pharmaceutical Group’s new product, Cinacalcet Hydrochloride Tablets, has been approved.

Next:

Shijiazhuang Fourth Pharmaceutical Group’s Sodium Acetate Ringer’s Injection Has Passed the Consistency Evaluation for Generic Drug Quality and Efficacy.